The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.
 
Niharika B. Mettu
Research Funding - Amgen (Inst); Amphivena (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); ERYTECH Pharma (Inst); Genentech (Inst); Incyte (Inst); Lucence Diagnostics (Inst); MedImmune (Inst); Repare Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
Sarina Anne Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Raghad Muhsin Abdul-Karim
No Relationships to Disclose
 
Gabriel Tinoco
Consulting or Advisory Role - Deciphera; Intellisphere
 
Michael Rahman Shafique
Consulting or Advisory Role - GlaxoSmithKline; Jazz Pharmaceuticals; Jazz Pharmaceuticals
Research Funding - Amphivena (Inst); Merck Serono (Inst); Nektar (Inst); Pfizer (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development; Nektar; Vaccinex
 
Victoria Smith
Employment - Amphivena Therapeutics
Leadership - Amphivena Therapeutics
Stock and Other Ownership Interests - Amphivena Therapeutics
 
Christina Baccei
Employment - Amphivena Therapeutics
Stock and Other Ownership Interests - Amphivena Therapeutics
 
Patrick Youngwhan Chun
Employment - Amphivena Therapeutics; Amphivena Therapeutics; Gilead Sciences; Merck Sharp & Dohme; Zentalis
Stock and Other Ownership Interests - Amphivena Therapeutics; Gilead Sciences; Zentalis
Travel, Accommodations, Expenses - Zentalis